特一药业(002728) - 2014 Q3 - 季度财报

Financial Performance - Operating revenue for the period was CNY 80,181,639.22, a 2.47% increase year-on-year[7] - Net profit attributable to shareholders decreased by 18.01% to CNY 17,056,912.52 compared to the same period last year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses fell by 23.43% to CNY 15,928,499.39[7] - Basic and diluted earnings per share were both CNY 0.19, down 32.14% year-on-year[7] - The weighted average return on equity was 2.82%, a decrease of 56.23% compared to the previous year[7] - The company's net profit attributable to shareholders for 2014 is expected to range from ¥80.55 million to ¥88.61 million, reflecting a growth of 0.00% to 10.00% compared to the previous year[17] Asset and Shareholder Information - Total assets increased by 81.05% to CNY 821,142,355.45 compared to the end of the previous year[7] - Net assets attributable to shareholders rose by 105.58% to CNY 719,806,129.55 year-on-year[7] - The total number of ordinary shareholders at the end of the reporting period was 13,557[10] - The largest shareholder, Xu Danqing, holds 31.05% of the shares, totaling 31,050,000 shares[10] Cash Flow and Financial Activities - Cash flow from operating activities for the year-to-date was CNY 56,515,623.00, an increase of 68.55%[7] - The company's cash and cash equivalents increased by 213.45%, reaching ¥510.31 million due to funds raised from a public stock offering[14] - The net cash flow from operating activities increased by 68.55% to ¥56.52 million, attributed to higher cash receipts from sales[14] - The net cash flow from financing activities improved by 33.77%, with a net outflow of -¥15.79 million, reflecting reduced payments for construction projects[14] - The company reported a 2100.07% increase in net cash flow from investing activities, totaling ¥306.78 million, due to funds raised from the public stock offering[14] Expenses and Income - Sales expenses rose by 34.16% to ¥22.77 million, primarily due to increased advertising expenditures[14] - The company reported a significant increase in other income, which rose by 5971.00% to ¥2.43 million, driven by increased government subsidies[14] - The capital reserve increased by 721.82% to ¥337.93 million, resulting from the premium on shares issued during the public offering[14] - The company experienced a 57.85% increase in financial income, with a net financial expense of -¥3.32 million due to growth in interest income[14] - Prepayments increased by 38.16% to ¥25.06 million, attributed to increased advance payments for raw material purchases[14]